Corrigendum to 'Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial' [eBioMedicine 127 (2026) 106268] doi: 10.1016/j.ebiom.2026.106268